Please login to the form below

Not currently logged in
Email:
Password:

GSK to appeal Alabama Medicaid judgement

GlaxoSmithKline has said it will appeal a court verdict against it regarding the way it reported prices for drugs reimbursed by Medicaid in the State of Alabama
GlaxoSmithKline (GSK) has said it will appeal a court verdict against it regarding the way it reported prices for drugs reimbursed by Medicaid in the State of Alabama.

The drug manufacturer is one of 73 pharmaceutical firms named in a lawsuit filed by the Alabama attorney general in January 2005. Both GSK and Novartis argued before the court in this round of litigation.

"We have said from the beginning that GSK reported true and accurate prices to the State of Alabama," said Chilton Varner, an attorney general with King & Spalding of Atlanta who represented GSK. "Evidence also shows that, although the state now says it was not being fairly treated, the state has not changed the rules since it filed the lawsuit more than three years ago."

Novartis was found liable for $33.2m in compensatory damages and no punitive damages by the Alabama Jury, which also found GSK liable for $80.9m compensatory damages with no punitive damages.

In February 2008, a separate jury ordered AstraZeneca (AZ) to pay the state $40m in compensatory damages and $175m in punitive damages. A state judge later reduced that amount to $120m because Alabama limits punitive damages to three-times the amount of compensatory damages.

2nd July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics